Inflammation as a therapeutic agent in cerebral infarction: Cellular inflammatory response and inflammatory mediators;La inflamación como agente terapéutico en el infarto cerebral: Respuesta inflamatoria celular y mediadores inflamatorios

Revista de Neurologia

Volumn 50, Issue 6, 2010, Pages 349-359

  Cuenca López, María D ^b   Brea, David ^a   Segura, Tomás ^c   Galindo, María F ^d   Antón Martínez, David ^e   Agulla, Jesús ^a   Castillo, José ^a   Jordán, Joaquín ^b,f,g  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Universidad de Castilla La Mancha   (Spain)

^c Servicio de Neurologia   (Spain)

^d Unidad de Neuropsicofarmacologia Traslacional   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^f University of Castilla La Mancha   (Spain)

^g UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

CNS; Cytokines; Inflammatory mediators; Inflammatory response; Interleukins; Ischaemia

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PROSTAGLANDIN SYNTHASE; TRANSCRIPTION FACTOR;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN INFARCTION; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE PRODUCTION; GENE OVEREXPRESSION; HEAD INJURY; IMMUNOREACTIVITY; INFECTION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; STROKE; TRANSCRIPTION INITIATION;

EID: 77950452350     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5006.2009666     Document Type: Review

References (121)

1. Perry VH. A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J Neuroimmunol 1998; 90: 113-121
2. Kaur C, Ling EA. Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res 2008; 5: 71-81.
3. Aloisi F. Immune function of microglia. Glia 2001; 36: 165-179
4. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19: 312-318
5. Dávalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005; 8: 752-758
6. Ling EA, Wong WC. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia 1993; 7: 9-18.
7. Schmidtmayer J, Jacobsen C, Miksch G, Sievers J. Blood monocytes and spleen macrophages differentiate into microglia-like cells on monolayers of astrocytes: membrane currents. Glia 1994; 12: 259-267
8. Streit WJ, Graeber MB. Heterogeneity of microglial and perivascular cell populations: insights gained from the facial nucleus paradigm. Glia 1993; 7: 68-74.
9. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988; 239: 290-292
10. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308: 1314-1318
11. Garden GA, Moller T. Microglia biology in health and disease. J Neuroimmune Pharmacol 2006; 1: 127-137
12. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 2003; 4: 103-112
13. Nakajima K, Kohsaka S. Microglia: activation and their significance in the central nervous system. J Biochem 2001; 130: 169-175
14. Banati RB, Gehrmann J, Kreutzberg GW. Early glial reactions in ischemic lesions. Adv Neurol 1996; 71: 329-337
15. Schroeter M, Zickler P, Denhardt DT, Hartung HP, Jander S. Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice. Brain 2006; 129: 1426-1437
16. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69: 1404-1410
17. Melero-Fernández de Mera RM, García-Martínez E, Fernández-Gómez FJ, Hernández-Guijo JM, Aguirre N, Galindo MF, et al. ¿Es la vieja minociclina un nuevo fármaco neuroprotector? Rev Neurol 2008; 47: 31-38
18. Jordán J, Fernández-Gómez FJ, Ramos M, Ikuta I, Aguirre N, Galindo MF. Minocycline and cytoprotection: shedding new light on a shadowy controversy. Curr Drug Deliv 2007; 4: 225-231
19. 2+ signalling in hippocampal neurons. Eur J Neurosci 2007; 26: 2481-2495
20. García-Martínez EM, Sanz-Blasco S, Karachitos A, Bandez MJ, Fernández-Gómez FJ, Pérez-Álvarez S, et al. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol 2010; 79: 239-250
21. Fernández-Gómez FJ, Galindo MF, Gómez-Lázaro M, González-García C, Ceña V, Aguirre N, et al. Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions. Neuroscience 2005; 133: 959-967
22. Che X, Ye W, Panga L, Wu D, Yang G. Monocyte chemo-attractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Res 2001; 902: 171-177
23. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005; 50: 427-434
24. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001; 36: 180-190
25. Hewett SJ, Muir JK, Lobner D, Symons A, Choi DW. Potentiation of oxygen-glucose deprivation-induced neuronal death after induction of iNOS. Stroke 1996; 27: 1586-1591
26. Akopov SE, Simonian NA, Grigorian GS. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke 1996; 27: 1739-1743
27. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19: 819-834
28. Del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang CM. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991; 22: 1276-1283
29. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992; 356: 768-774
30. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-1652
31. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266: 10331-10336
32. Koga S, Ogawa S, Kuwabara K, Brett J, Leavy JA, Ryan J, et al. Synthesis and release of interleukin 1 by reoxygenated human mononuclear phagocytes. J Clin Invest 1992; 90: 1007-1015
33. Rothwell NJ. Functions and mechanisms of interleukin 1 in the brain. Trends Pharmacol Sci 1991; 12: 430-436
34. Minami M, Kuraishi Y, Satoh M. Effects of kainic acid on messenger RNA levels of IL-1 beta, IL-6, TNF alpha and LIF in the rat brain. Biochem Biophys Res Commun 1991; 176: 593-598
35. Buttini M, Boddeke H. Peripheral lipopolysaccharide stimulation induces interleukin-1 beta messenger RNA in rat brain microglial cells. Neuroscience 1995; 65: 523-530
36. Buttini M, Sauter A, Boddeke HW. Induction of interleukin-1 beta mRNA after focal cerebral ischaemia in the rat. Brain Res Mol Brain Res 1994; 23: 126-134
37. Davies CA, Loddick SA, Toulmond S, Stroemer RP, Hunt J, Rothwell NJ. The progression and topographic distribution of interleukin-1beta expression after permanent middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1999; 19: 87-98.
38. Haqqani AS, Nesic M, Preston E, Baumann E, Kelly J, Stanimirovic D. Characterization of vascular protein expression patterns in cerebral ischemia/reperfusion using laser capture microdissection and icat-nanolc-ms/ms. FASEB J 2005; 19: 1809-1821
39. Azzimondi G, Bassein L, Nonino F, Fiorani L, Vignatelli L, Re G, et al. Fever in acute stroke worsens prognosis. A prospective study. Stroke 1995; 26: 2040-2043
40. Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995; 26: 676-681.
41. Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol 1999; 163: 3963-3968
42. Strijbos PJ, Rothwell NJ. Interleukin-1 beta attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor. J Neurosci 1995; 15: 3468-3474
43. Yang GY, Zhao YJ, Davidson BL, Betz AL. Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury. Brain Res 1997; 751: 181-188
44. Relton JK, Martin D, Thompson RC, Russell DA. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 1996; 138: 206-213
45. Pinteaux E, Rothwell NJ, Boutin H. Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1RA) are mediated by glia. Glia 2006; 53: 551-556
46. Herrmann O, Tarabin V, Suzuki S, Attigah N, Coserea I, Schneider A, et al. Regulation of body temperature and neuroprotection by endogenous interleukin-6 in cerebral ischemia. J Cereb Blood Flow Metab 2003; 23: 406-415
47. Wang X, Yue TL, Barone FC, White RF, Gagnon RC, Feuerstein GZ. Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Mol Chem Neuropathol 1994; 23: 103-114
48. Vila N, Castillo J, Dávalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325-2329
49. Castillo J, Rodríguez I. Biochemical changes and inflammatory response as markers for brain ischaemia. Molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004; 17 (Suppl 1): 7-18.
50. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004; 4: 2.
51. Sriram K, O'Callaghan JP. Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol 2007; 2: 140-153
52. Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC, et al. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 1994; 25: 1481-1488
53. Buttini M, Appel K, Sauter A, Gebicke-Haerter PJ, Boddeke HW. Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. Neuroscience 1996; 71: 1-16.
54. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, et al. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 1997; 28: 1233-1244
55. Liu T, McDonnell PC, Young PR, White RF, Siren AL, Hallenbeck JM, et al. Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke 1993; 24: 1746-1751
56. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40-47
57. Murakami Y, Saito K, Hara A, Zhu Y, Sudo K, Niwa M, et al. Increases in tumor necrosis factor-alpha following transient global cerebral ischemia do not contribute to neuron death in mouse hippocampus. J Neurochem 2005; 93: 1616-1622
58. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab 2006; 26: 654-665
59. Tomimoto H, Akiguchi I, Wakita H, Kinoshita A, Ikemoto A, Nakamura S, et al. Glial expression of cytokines in the brains of cerebrovascular disease patients. Acta Neuropathol 1996; 92: 281-287
60. Sairanen T, Carpen O, Karjalainen-Lindsberg ML, Paetau A, Turpeinen U, Kaste M, et al. Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke. Stroke 2001; 32: 1750-1758
61. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, et al. Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol 1997; 110: 492-499
62. Van Exel E, Gussekloo J, De Craen AJ, Bootsma-Van der Wiel A, Frolich M, Westendorp RG. Inflammation and stroke: the Leiden 85-plus study. Stroke 2002; 33: 1135-1138
63. Castellanos M, Castillo J, García MM, Leira R, Serena J, Chamorro A, et al. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002; 33: 982-987
64. Yang GY, Gong C, Qin Z, Ye W, Mao Y, Bertz AL. Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport 1998; 9: 2131-2134
65. Lavine SD, Hofman FM, Zlokovic BV. Circulating antibody against tumor necrosis factor-alpha protects rat brain from reperfusion injury. J Cereb Blood Flow Metab 1998; 18: 52-58
66. Wang CX, Shuaib A. Involvement of inflammatory cytokines in central nervous system injury. Prog Neurobiol 2002; 67: 161-172
67. Ginis I, Jaiswal R, Klimanis D, Liu J, Greenspon J, Hallenbeck JM. TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-κB transactivation: THE role of NF-kappaB association with p300 adaptor. J Cereb Blood Flow Metab 2002; 22: 142-152
68. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996; 2: 788-794
69. Klempt ND, Sirimanne E, Gunn AJ, Klempt M, Singh K, Williams C, et al. Hypoxia-ischemia induces transforming growth factor beta 1 mRNA in the infant rat brain. Brain Res Mol Brain Res 1992; 13: 93-101.
70. Wiessner C, Gehrmann J, Lindholm D, Topper R, Kreutzberg GW, Hossmann KA. Expression of transforming growth factor-beta 1 and interleukin-1 beta mRNA in rat brain following transient forebrain ischemia. Acta Neuropathol 1993; 86: 439-446
71. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83: 113-118
72. Pang L, Ye W, Che XM, Roessler BJ, Betz AL, Yang GY. Reduction of inflammatory response in the mouse brain with adenoviral-mediated transforming growth factor-SS1 expression. Stroke 2001; 32: 544-552
73. Lu YZ, Lin CH, Cheng FC, Hsueh CM. Molecular mechanisms responsible for microglia-derived protection of Sprague-Dawley rat brain cells during in vitro ischemia. Neurosci Lett 2005; 373: 159-164
74. Mori E, Del Zoppo GJ, Chambers JD, Copeland BR, Arfors KE. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke 1992; 23: 712-718
75. Johnston RE, Dillon-Carter O, Freed WJ, Borlongan CV. Trophic factor secreting kidney cell lines: in vitro characterization and functional effects following transplantation in ischemic rats. Brain Res 2001; 900: 268-276
76. Gross CE, Bednar MM, Howard DB, Sporn MB. Transforming growth factor-beta 1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke 1993; 24: 558-562
77. Benveniste EN. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev 1998; 9: 259-275
78. Brea D, Sobrino T, Ramos-Cabrer P, Castillo J. Reorganización de la vascularización cerebral tras la isquemia. Rev Neurol 2009; 49: 645-654
79. Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, Freund GG, et al. Interleukin-10 in the brain. Crit Rev Immunol 2001; 21: 427-449
80. Vila N, Castillo J, Dávalos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003; 34: 671-675
81. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 1998; 251: 189-192
82. Ooboshi H, Ibayashi S, Shichita T, Kumai Y, Takada J, Ago T, et al. Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation 2005; 111: 913-919
83. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6, transforming growth factor-beta, and S-100 protein in patients with acute stroke. Stroke 1996; 27: 1553-1557
84. Grilli M, Barbieri I, Basudev H, Brusa R, Casati C, Lozza G, et al. Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. Eur J Neurosci 2000; 12: 2265-2272
85. Emsley HC, Tyrrell PJ. Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab 2002; 22: 1399-1419
86. Garau A, Bertini R, Colotta F, Casilli F, Bigini P, Cagnotto A, et al. Neuroprotection with the CXCl8 inhibitor repertaxin in transient brain ischemia. Cytokine 2005; 30: 125-131
87. Losy J, Zaremba J. Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke. Stroke 2001; 32: 2695-2696
88. Stamatovic SM, Shakui P, Keep RF, Moore BB, Kunkel SL, Van Rooijen N, et al. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab 2005; 25: 593-606.
89. Wang L, Li Y, Chen J, Gautam SC, Zhang Z, Lu M, et al. Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. Exp Hematol 2002; 30: 831-836
90. Re DB, Przedborski S. Fractalkine: moving from chemotaxis to neuroprotection. Nat Neurosci 2006; 9: 859-861
91. Tarozzo G, Campanella M, Ghiani M, Bulfone A, Beltramo M. Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat. Eur J Neurosci 2002; 15: 1663-1668
92. Lavergne E, Labreuche J, Daoudi M, Debre P, Cambien F, Deterre P, et al. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 847-853
93. Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, et al. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 2002; 125: 59-65.
94. Schwab JM, Beschorner R, Meyermann R, Gozalan F, Schluesener HJ. Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury. J Neurosurg 2002; 96: 892-899
95. Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1991; 1083: 1-17.
96. Iadecola C, Sugimoto K, Niwa K, Kazama K, Ross ME. Increased susceptibility to ischemic brain injury in cyclooxygenase-1-deficient mice. J Cereb Blood Flow Metab 2001; 21: 1436-1441
97. Candelario-Jalil E, González-Falcón A, García- Cabrera M, Álvarez D, Al-Dalain S, Martínez G, et al. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J Neurochem 2003; 86: 545-555
98. Planas AM, Soriano MA, Rodríguez-Farré E, Ferrer I. Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain. Neurosci Lett 1995; 200: 187-190
99. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997; 17: 2746-2755
100. Sairanen T, Ristimaki A, Karjalainen-Lindsberg ML, Paetau A, Kaste M, Lindsberg PJ. Cyclooxygenase-2 is induced globally in infarcted human brain. Ann Neurol 1998; 43: 738-747
101. Sugimoto K, Iadecola C. Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia. Brain Res 2003; 960: 273-276
102. Dore S, Otsuka T, Mito T, Sugo N, Hand T, Wu L, et al. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 2003; 54: 155-162
103. Llorens S, Jordán J, Nava E. The nitric oxide pathway in the cardiovascular system. J Physiol Biochem 2002; 58: 179-188
104. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997; 100: 2417-2423
105. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 1997; 20: 132-139
106. Cui J, Holmes EH, Greene TG, Liu PK. Oxidative DNA damage precedes DNA fragmentation after experimental stroke in rat brain. FASEB J 2000; 14: 955-967
107. Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-l-arginine. J Cereb Blood Flow Metab 1996; 16: 981-987
108. Iadecola C, Zhang F, Casey R, Nagayama M, Ross ME. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997; 17: 9157-9164
109. Parmentier S, Bohme GA, Lerouet D, Damour D, Stutzmann JM, Margaill I, et al. Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. Br J Pharmacol 1999; 127: 546-552
110. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996; 16: 360-366
111. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase a (MMP-2) and gelatinase β (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 1997; 238: 53-56
112. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003; 34: 40-46
113. Montaner J, Álvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001; 32: 1759-1766
114. Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003; 34: 2025-2030
115. Asahi M, Sumii T, Fini ME, Itohara S, Lo EH. Matrix metallo-proteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport 2001; 12: 3003-3007
116. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006; 12: 441-445
117. Gómez-Lázaro M, Fernández-Gómez FJ, Jordán J. p53: twenty five years understanding the mechanism of genome protection. J Physiol Biochem 2004; 60: 287-307.
118. Tureyen K, Kapadia R, Bowen KK, Satriotomo I, Liang J, Feinstein DL, et al. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007; 101: 41-56.
119. O'Mahony A, Raber J, Montano M, Foehr E, Han V, Lu SM, et al. NF-kappaB/rel regulates inhibitory and excitatory neuronal function and synaptic plasticity. Mol Cell Biol 2006; 26: 7283-7298
120. Jordán J, Segura T, Brea D, Galindo MF, Castillo J. Inflammation as therapeutic objective in stroke. Curr Pharm Des 2008; 14: 3549-3564
121. Fernández-Gómez FJ, Hernández F, Argandoña L, Galindo MF, Segura T, Jordán J. Farmacología de la neuroprotección en el ictus isquémico agudo. Rev Neurol 2008; 47: 253-260